原文出处：U.S. Food and Drug Administration (FDA) Approves Reblozyl? (luspatercept-aamt) , the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
原标题：贫血新药！BMS首创红细胞成熟剂Reblozyl获美国FDA批准，治疗骨髓增生异常综合症(MDS)相关贫血！
本文来源自生物谷，更多资讯请下载生物谷APP(
http://www.bioon.com/m/)
